Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 8/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18459337 | 0.81 | YAP1 (0.48) | CTSSCTSKCYP3A4TSHR | |
| SCHEMBL18459339 | 0.81 | YAP1 (0.48) | CTSSCTSKCYP3A4TSHR | |
| SCHEMBL15084008 | 0.78 | ACACB (0.72) | ACACB | |
| SCHEMBL29023032 | 0.74 | ITGB3 (0.61) | CTSSCYP3A4TSHRACACBATM | |
| SCHEMBL28395757 | 0.74 | ATM (0.56) | CTSSCTSKCYP3A4TSHRACACB | |
| SCHEMBL7414382 | 0.74 | CA1 (0.70) | CTSSCTSKCYP3A4TSHRACACB | |
| SCHEMBL29023018 | 0.73 | ACACB (0.54) | CTSSCYP3A4TSHRACACBATM | |
| SCHEMBL8530402 | 0.73 | ATM (0.68) | CTSSCTSKCYP3A4TSHRATM | |
| SCHEMBL21469067 | 0.73 | ATM (0.68) | CTSSCTSKCYP3A4TSHRATM | |
| SCHEMBL30460502 | 0.73 | ATM (0.68) | CTSSCTSKCYP3A4TSHRATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | IDH1, IDH3A, IDH3B | CTSS 4697/4885CTSK 4605/4885CYP3A4 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.